Redmile Group, LLC
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Redmile Group, LLC reported 56 stock positions worth $1.1 billion. Its top holding was Scholar Rock (SRRK) at 13.4% of the portfolio, followed by Krystal Biotech (KRYS, 12.6%) and Amicus Therapeutics (FOLD, 7.4%). Compared with Q4 2024, it opened 3 new positions, sold out of 9, added to 7 and reduced 31. The biggest buy was Amicus Therapeutics (FOLD, shares +35%) and the biggest sale Pliant Therapeutics (PLRX, shares −29%).
- Most Recent 13F
- Q2 2026
- Location
- LARKSPUR, CA
- CIK
- 0001425738
- Portfolio Value
- $1.1B (Q1 2025)
- SEC Filing
- 0001104659-25-049578 ↗ filed May 15, 2025
Holdings Value
Holdings 56 stocks · $1.1B
| SRRK Scholar Rock Holding Corp. | 13.37% | 4,398,281 | $141.4M | Reduce -3.3% |
| KRYS Krystal Biotech Inc. | 12.57% | 737,675 | $133.0M | Reduce -2.1% |
| FOLD Amicus Therapeutics Inc. | 7.35% | 9,533,669 | $77.8M | Add +35.1% |
| ZYME Zymeworks Inc. | 5.39% | 4,788,945 | $57.0M | Reduce -1.1% |
| NRIX Nurix Therapeutics Inc. | 4.55% | 4,051,927 | $48.1M | Reduce -3.4% |
| REPL Replimune Group Inc. | 4.51% | 4,898,527 | $47.8M | Reduce -0.1% |
| LIVN Livanova PLC | 3.77% | 1,014,139 | $39.8M | Reduce -2.8% |
| AKRO Akero Therapeutics Inc. | 3.59% | 939,277 | $38.0M | Reduce -24.0% |
| IMNM Immunome Inc. | 3.41% | 5,361,187 | $36.1M | Add +11.0% |
| RGNX Regenxbio Inc. | 3.24% | 4,794,780 | $34.3M | No change |
| BEAM Beam Therapeutics Inc. | 2.97% | 1,610,329 | $31.4M | Add +5.3% |
| STOK Stoke Therapeutics Inc. | 2.82% | 4,485,981 | $29.8M | Reduce -2.3% |
| KYMR Kymera Therapeutics Inc. | 2.54% | 983,413 | $26.9M | Reduce -10.6% |
| ADCT Adc Therapeutics SA | 2.09% | 15,666,731 | $22.1M | No change |
| BHVN Biohaven Ltd. | 1.97% | 867,454 | $20.9M | Reduce -4.1% |
| ABSI Absci Corp. | 1.96% | 8,253,316 | $20.7M | No change |
| BSX Boston Scientific Corp. | 1.84% | 193,283 | $19.5M | Reduce -38.2% |
| COGT Cogent Biosciences Inc. | 1.82% | 3,216,026 | $19.3M | Reduce -9.5% |
| NGNE Neurogene Inc. | 1.45% | 1,308,063 | $15.3M | Reduce -0.9% |
| ETNB 89BIO Inc. | 1.30% | 1,886,444 | $13.7M | Reduce -12.9% |
| ESTA Establishment Labs Holdings | 1.29% | 335,366 | $13.7M | Add +4.8% |
| ANNX Annexon Inc. | 1.15% | 6,300,644 | $12.2M | No change |
| CLDX Celldex Therapeutics Inc. | 1.01% | 590,175 | $10.7M | Reduce -4.2% |
| FATE Fate Therapeutics Inc. | 0.96% | 12,872,946 | $10.2M | No change |
| IDYA Ideaya Biosciences Inc. | 0.83% | 534,600 | $8.8M | Reduce -13.7% |
| IMVT Immunovant Inc. | 0.79% | 490,394 | $8.4M | Reduce -14.2% |
| CBLL Ceribell Inc. | 0.79% | 435,239 | $8.4M | No change |
| RAPT THERAPEUTICS INC | 0.75% | 6,475,317 | $7.9M | No change |
| SLDB Solid Biosciences Inc. | 0.71% | 2,019,171 | $7.5M | Add +228.2% |
| PODD Insulet Corp. | 0.67% | 27,109 | $7.1M | Add +183.6% |
| BNTX Biontech SE-ADR | 0.63% | 73,071 | $6.7M | Reduce -12.5% |
| SLN Silence Therapeutics PLC-ADR | 0.59% | 2,214,947 | $6.2M | Reduce -7.7% |
| PEN Penumbra Inc. | 0.58% | 22,843 | $6.1M | Reduce -11.3% |
| IRTC Irhythm Holdings Inc. | 0.56% | 56,844 | $6.0M | New |
| KROS Keros Therapeutics Inc. | 0.53% | 552,506 | $5.6M | No change |
| VERV Verve Therapeutics Inc. | 0.52% | 1,207,164 | $5.5M | Reduce -8.4% |
| NUVB Nuvation Bio Inc. | 0.50% | 3,031,009 | $5.3M | No change |
| STTK Shattuck Labs Inc. | 0.50% | 5,539,724 | $5.3M | No change |
| MASI Masimo Corp. | 0.41% | 26,062 | $4.3M | New |
| PRME Prime Medicine Inc. | 0.39% | 2,074,350 | $4.1M | No change |
| ORKA Oruka Therapeutics Inc. | 0.38% | 386,963 | $4.0M | Reduce -6.0% |
| IGMS Igm Biosciences Inc. | 0.32% | 2,952,131 | $3.4M | No change |
| CYTK Cytokinetics Inc. | 0.31% | 82,098 | $3.3M | Reduce -11.3% |
| FDMT 4D Molecular Therapeutics Inc. | 0.30% | 997,235 | $3.2M | Reduce -16.7% |
| PLRX Pliant Therapeutics Inc. | 0.26% | 2,053,559 | $2.8M | Reduce -29.1% |
| LVTX Lava Therapeutics NV | 0.25% | 2,074,372 | $2.6M | No change |
| ATRA Atara Biotherapeutics Inc. | 0.25% | 441,701 | $2.6M | No change |
| XERS Xeris Biopharma Holdings Inc. | 0.23% | 451,099 | $2.5M | No change |
| ALXO Alx Oncology Holdings Inc. | 0.21% | 3,640,834 | $2.3M | Reduce -1.3% |
| RPTX Repare Therapeutics Inc. | 0.18% | 1,884,389 | $1.9M | Reduce -1.6% |
| VTYX Ventyx Biosciences Inc. | 0.17% | 1,569,793 | $1.8M | Add +1164.2% |
| ATXS Astria Therapeutics Inc. | 0.14% | 269,078 | $1.4M | Reduce -22.3% |
| IVVD Invivyd Inc. | 0.13% | 2,285,320 | $1.4M | Reduce -24.1% |
| BOLD Boundless Bio Inc. | 0.10% | 725,204 | $1.1M | Reduce -2.0% |
| KLRS Kalaris Therapeutics Inc. | 0.06% | 82,955 | $666K | New |
| ALLK Allakos LLC | 0.02% | 856,615 | $195K | Reduce -71.6% |
Portfolio Sells Q4 2024 → Q1 2025
| PLRX Pliant Therapeutics Inc. | Reduce -29.1% | 0.26% | −2.40 |
| NRIX Nurix Therapeutics Inc. | Reduce -3.4% | 4.55% | −0.96 |
| SYK Stryker Corp. | Sold out | 0.00% | −0.77 |
| STOK Stoke Therapeutics Inc. | Reduce -2.3% | 2.82% | −0.71 |
| NGNE Neurogene Inc. | Reduce -0.9% | 1.45% | −0.65 |
| ISRG Intuitive Surgical Inc. | Sold out | 0.00% | −0.62 |
| SLN Silence Therapeutics PLC-ADR | Reduce -7.7% | 0.59% | −0.56 |
| ARDX Ardelyx Inc. | Sold out | 0.00% | −0.56 |
| KYMR Kymera Therapeutics Inc. | Reduce -10.6% | 2.54% | −0.54 |
| BHVN Biohaven Ltd. | Reduce -4.1% | 1.97% | −0.38 |
| SRRK Scholar Rock Holding Corp. | Reduce -3.3% | 13.37% | −0.34 |
| STXS Stereotaxis Inc. | Sold out | 0.00% | −0.29 |
| IDYA Ideaya Biosciences Inc. | Reduce -13.7% | 0.83% | −0.28 |
| ALLK Allakos LLC | Reduce -71.6% | 0.02% | −0.24 |
| ALXO Alx Oncology Holdings Inc. | Reduce -1.3% | 0.21% | −0.21 |
| IMVT Immunovant Inc. | Reduce -14.2% | 0.79% | −0.20 |
| ACIU Ac Immune SA | Sold out | 0.00% | −0.19 |
| ORKA Oruka Therapeutics Inc. | Reduce -6.0% | 0.38% | −0.18 |
| FDMT 4D Molecular Therapeutics Inc. | Reduce -16.7% | 0.30% | −0.16 |
| ACHL Achilles Therapeutics PL-ADR | Sold out | 0.00% | −0.13 |
| COGT Cogent Biosciences Inc. | Reduce -9.5% | 1.82% | −0.11 |
| BSX Boston Scientific Corp. | Reduce -38.2% | 1.84% | −0.10 |
| ATXS Astria Therapeutics Inc. | Reduce -22.3% | 0.14% | −0.08 |
| CLDX Celldex Therapeutics Inc. | Reduce -4.2% | 1.01% | −0.07 |
| ALLOVIR INC | Sold out | 0.00% | −0.06 |
| BOLD Boundless Bio Inc. | Reduce -2.0% | 0.10% | −0.05 |
| BNTX Biontech SE-ADR | Reduce -12.5% | 0.63% | −0.03 |
| ADAPY Adaptimmune Therapeutics-ADR | Sold out | 0.00% | −0.03 |
| HOOK Hookipa Pharma Inc. | Sold out | 0.00% | −0.01 |
| RPTX Repare Therapeutics Inc. | Reduce -1.6% | 0.18% | +0.00 |
| VERV Verve Therapeutics Inc. | Reduce -8.4% | 0.52% | +0.00 |
| CYTK Cytokinetics Inc. | Reduce -11.3% | 0.31% | +0.01 |
| IVVD Invivyd Inc. | Reduce -24.1% | 0.13% | +0.04 |
| ETNB 89BIO Inc. | Reduce -12.9% | 1.30% | +0.12 |
| PEN Penumbra Inc. | Reduce -11.3% | 0.58% | +0.15 |
| REPL Replimune Group Inc. | Reduce -0.1% | 4.51% | +0.37 |
| LIVN Livanova PLC | Reduce -2.8% | 3.77% | +0.40 |
| ZYME Zymeworks Inc. | Reduce -1.1% | 5.39% | +0.45 |
| AKRO Akero Therapeutics Inc. | Reduce -24.0% | 3.59% | +1.20 |
| KRYS Krystal Biotech Inc. | Reduce -2.1% | 12.57% | +4.35 |
Portfolio Buys Q4 2024 → Q1 2025
| FOLD Amicus Therapeutics Inc. | Add +35.1% | 7.35% | +2.72 |
| IRTC Irhythm Holdings Inc. | New | 0.56% | +0.56 |
| SLDB Solid Biosciences Inc. | Add +228.2% | 0.71% | +0.53 |
| PODD Insulet Corp. | Add +183.6% | 0.67% | +0.50 |
| MASI Masimo Corp. | New | 0.41% | +0.41 |
| BEAM Beam Therapeutics Inc. | Add +5.3% | 2.97% | +0.33 |
| ESTA Establishment Labs Holdings | Add +4.8% | 1.29% | +0.27 |
| VTYX Ventyx Biosciences Inc. | Add +1164.2% | 0.17% | +0.15 |
| KLRS Kalaris Therapeutics Inc. | New | 0.06% | +0.06 |
| IMNM Immunome Inc. | Add +11.0% | 3.41% | −0.16 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $1.5B | SRRK, KRYS, STOK, IMNM, NRIX |
| Q1 2026 | 35 | $1.5B | SRRK, KRYS, STOK, IMNM, NRIX |
| Q4 2025 | 34 | $1.4B | SRRK, KRYS, NRIX, STOK, IMNM |
| Q3 2025 | 40 | $1.0B | SRRK, KRYS, STOK, ZYME, ADCT |
| Q2 2025 | 48 | $939.6M | SRRK, KRYS, ZYME, STOK, IMNM |
| Q1 2025 | 56 | $1.1B | SRRK, KRYS, FOLD, ZYME, NRIX |
| Q4 2024 | 62 | $1.4B | SRRK, KRYS, NRIX, ZYME, FOLD |
| Q3 2024 | 63 | $1.7B | KRYS, NRIX, FOLD, IMNM, KYMR |
| Q2 2024 | 63 | $1.7B | KRYS, FOLD, NRIX, STOK, IMNM |
| Q1 2024 | 77 | $2.7B | KRYS, FOLD, IMNM, SRRK, FATE |